IGM Biosciences在与Concentra的合并协议中取得进展

2025-07-02 00:19

Micro-cap cancer drug developer IGM Biosciences (NASDAQ:IGMS) added ~21% after Concentra Biosciences agreed to acquire the company for $1.247 in cash upfront plus a non-tradeable contingent value right (CVR) per share.
Under the terms, Concentra, an entity controlled by hedge fund Tang Capital Partners, will begin a tender offer by July 16 to acquire all outstanding shares of IGM Biosciences’ (NASDAQ:IGMS) common stock.
The transaction is expected to complete in August, subject to several closing conditions, including the tender of voting common stock that represents a majority of the company's outstanding shares.
The CVR arrangement allows IGMS investors to receive 100% of the company’s net cash, worth more than $82M, and 80% of any net proceeds generated from divesting its product candidates and IP rights.

More on IGM Biosciences